Abstract 17332: Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Death in Patients after an Acute Coronary Syndrome
Introduction: Plasma omega-3 polyunsaturated fatty acids (Ω3-PUFA) have been inversely correlated with the risk of cardiovascular death in primary prevention populations. The prognostic value of Ω3-PUFA in patients with an acute coronary syndrome (ACS) is not well established.
Methods: Baseline plasma Ω3-PUFA composition (including plant-derived ALA and the 3 long-chain marine-based Ω3-PUFAs EPA, DPA, & DHA) was assessed through thin liquid chromatography in a case control population (203 CV deaths & 1612 controls) from MERLIN-TIMI 36, a randomized trial of ranolazine versus placebo in patients hospitalized with an ACS. Median follow-up was 1 year. Analyses were adjusted for age, sex, BMI, traditional cardiac risk factors and cardiac history, lipids, renal function, and index diagnosis.
Results: After multivariable adjustment, patients with higher plasma fractions of each Ω3-PUFA tended to have lower odds of CV death. When all 4 Ω3-PUFAs were combined, the highest fractional levels (Q4 vs Q1-Q3) of total Ω3-PUFA (OR 0.63, 0.41-0.97) and long-chain Ω3-PUFA (OR 0.58, 0.37-0.89) were significantly associated with reduced odds of CV death (Figure). In contrast, Ω3-PUFA plasma fraction was not significantly associated with the odds of MI, atrial fibrillation, or ventricular tachycardia.
Conclusions: In patients after ACS, a higher proportion of plasma Ω3-PUFA is associated with lower odds of CV death, independent of traditional risk factors and lipids. These data support the rationale for ongoing studies to assess whether Ω3-PUFA supplementation will translate into a mortality benefit in this population.
Author Disclosures: M.L. O’Donoghue: Research Grant; Significant; GlaxoSmithKline, Eisai, AstraZeneca. Honoraria; Modest; diaDexus. Consultant/Advisory Board; Modest; Aegerion. D.A. Morrow: Research Grant; Significant; Abbott, Amgen, AstraZeneca, Beckman Coulter, BG Medicine, BRAHMS, Bristol-Myers Squibb, Critical Diagnostics, CV Therapeutics, Daiichi Sankyo Co Ltd, Eli Lilly and Co, GlaxoSmithKline,, Johnson & Johnson, Merck and Co, Novartis Pharmaceuticals, Roche Diagnostics, Sanofi-Aventis, Singulex, and Takeda.. Consultant/Advisory Board; Modest; Abbott Laboratories, DiaDexus, Eli Lilly, Gilead, Instrumentation Laboratory, Konica Minolta, Johnson & Johnson, Merck, Roche Diagnostics, and Servier. B.M. Scirica: Research Grant; Significant; Gilead, Merck, Eisai, AstraZeneca, BMS. Consultant/Advisory Board; Modest; Gilead. J. Furtado: None. J. Guo: None. D. Mozaffarian: Honoraria; Modest; Bunge, Pollock Institute, and Quaker Oats. Consultant/Advisory Board; Modest; Foodminds, Nutrition Impact, Amarin, Astra Zeneca, and Life Sciences Research Organization. M.S. Sabatine: Research Grant; Significant; Abbott Laboratories; Amgen; AstraZeneca; AstraZeneca / Bristol-Myers Squibb Alliance;, Critical Diagnostics; Daiichi-Sankyo; Eisai; Genzyme; GlaxoSmithKline; Intarcia; Merck; Roche Diagnostics; Sanofi-aventis; Takeda. Consultant/Advisory Board; Modest; Amgen; AstraZeneca; Bristol-Myers Squibb; Intarcia; MyoKardia; Pfizer; Sanofi-aventis; Zeus.
- © 2014 by American Heart Association, Inc.